Almac
Almac Group, often referred to simply as Almac, is a leading global contract development and manufacturing organisation headquartered in the United States. Established in 2004, Almac has expanded its operational footprint across key regions, including Europe and Asia, solidifying its presence in the pharmaceutical and biotechnology sectors. Specialising in drug development, clinical trial services, and commercial manufacturing, Almac distinguishes itself through its innovative solutions and commitment to quality. The company has achieved significant milestones, including the successful launch of numerous life-saving therapies, positioning itself as a trusted partner for clients in the healthcare industry. With a strong emphasis on customer collaboration and cutting-edge technology, Almac continues to enhance its market position, making a notable impact on the global landscape of drug development and manufacturing.
DitchCarbon Score
How does Almac's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Almac's score of 53 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Almac's reported carbon emissions
In 2023, Almac Group Limited reported total carbon emissions of approximately 164,057,000 kg CO2e. This includes Scope 1 emissions of about 12,728,000 kg CO2e, Scope 2 emissions of approximately 17,434,000 kg CO2e, and significant Scope 3 emissions totalling around 133,895,000 kg CO2e. The Scope 3 emissions breakdown includes capital goods (about 19,345,000 kg CO2e), business travel (approximately 3,168,000 kg CO2e), and purchased goods and services (around 66,308,000 kg CO2e). Almac has set ambitious climate commitments, aiming for a 50% reduction in absolute Scope 1 and 2 emissions by 2030, using 2019 as the baseline year. Additionally, they have committed to achieving net-zero emissions across all scopes by 2045. This long-term target includes a 95% reduction in Scope 1 and 2 emissions and a 90% reduction in Scope 3 emissions by the same year. These targets are aligned with the Science Based Targets initiative (SBTi), which confirms that Almac's near-term targets are consistent with the reductions required to limit global warming to 1.5°C. The company is actively working towards these goals, demonstrating a strong commitment to sustainability and climate action within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 13,675,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 19,146,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 149,516,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Almac is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
